CTSO has 36-month beta value of 0.60. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTSO is 46.46M, and currently, short sellers hold a 3.34% ratio of that float. The average trading volume of CTSO on May 10, 2024 was 99.19K shares.
CTSO) stock’s latest price update
Cytosorbents Corp (NASDAQ: CTSO)’s stock price has dropped by -7.10 in relation to previous closing price of 0.87. Nevertheless, the company has seen a loss of -1.15% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-26 that PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024.
CTSO’s Market Performance
Cytosorbents Corp (CTSO) has experienced a -1.15% fall in stock performance for the past week, with a -15.62% drop in the past month, and a -20.59% drop in the past quarter. The volatility ratio for the week is 12.46%, and the volatility levels for the past 30 days are at 9.26% for CTSO. The simple moving average for the last 20 days is -3.93% for CTSO’s stock, with a simple moving average of -46.55% for the last 200 days.
Analysts’ Opinion of CTSO
Many brokerage firms have already submitted their reports for CTSO stocks, with B. Riley Securities repeating the rating for CTSO by listing it as a “Buy.” The predicted price for CTSO in the upcoming period, according to B. Riley Securities is $4 based on the research report published on September 07, 2023 of the previous year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CTSO reach a price target of $10. The rating they have provided for CTSO stocks is “Buy” according to the report published on October 14th, 2021.
Jefferies gave a rating of “Buy” to CTSO, setting the target price at $15 in the report published on September 17th of the previous year.
CTSO Trading at -10.82% from the 50-Day Moving Average
After a stumble in the market that brought CTSO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.12% of loss for the given period.
Volatility was left at 9.26%, however, over the last 30 days, the volatility rate increased by 12.46%, as shares sank -10.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -16.49% lower at present.
During the last 5 trading sessions, CTSO fell by -1.15%, which changed the moving average for the period of 200-days by -78.28% in comparison to the 20-day moving average, which settled at $0.8384. In addition, Cytosorbents Corp saw -27.03% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CTSO starting from Chan Phillip P., who purchase 75,188 shares at the price of $1.33 back on Dec 13 ’23. After this action, Chan Phillip P. now owns 1,068,704 shares of Cytosorbents Corp, valued at $100,000 using the latest closing price.
BATOR MICHAEL G., the Director of Cytosorbents Corp, purchase 37,594 shares at $1.33 during a trade that took place back on Dec 13 ’23, which means that BATOR MICHAEL G. is holding 125,394 shares at $50,000 based on the most recent closing price.
Stock Fundamentals for CTSO
Current profitability levels for the company are sitting at:
- -0.96 for the present operating margin
- 0.57 for the gross margin
The net margin for Cytosorbents Corp stands at -0.86. The total capital return value is set at -0.8. Equity return is now at value -97.21, with -47.43 for asset returns.
Based on Cytosorbents Corp (CTSO), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -4.0. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is 63.37.
Currently, EBITDA for the company is -28.53 million with net debt to EBITDA at -0.14. When we switch over and look at the enterprise to sales, we see a ratio of 1.49. The receivables turnover for the company is 5.35for trailing twelve months and the total asset turnover is 0.61. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.77.
Conclusion
To put it simply, Cytosorbents Corp (CTSO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
